Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains.

The 2.8-A crystal structure of the complex formed by estradiol and the human estrogen receptor-alpha ligand binding domain (hERalphaLBD) is described and compared with the recently reported structure of the progesterone complex of the human progesterone receptor ligand binding domain, as well as with similar structures of steroid/nuclear receptor LBDs solved elsewhere. The hormone-bound hERalphaLBD forms a distinctly different and probably more physiologically important dimer interface than its progesterone counterpart. A comparison of the specificity determinants of hormone binding reveals a common structural theme of mutually supported van der Waals and hydrogen-bonded interactions involving highly conserved residues. The previously suggested mechanism by which the estrogen receptor distinguishes estradiol's unique 3-hydroxy group from the 3-keto function of most other steroids is now described in atomic detail. Mapping of mutagenesis results points to a coactivator-binding surface that includes the region around the "signature sequence" as well as helix 12, where the ligand-dependent conformation of the activation function 2 core is similar in all previously solved steroid/nuclear receptor LBDs. A peculiar crystal packing event displaces helix 12 in the hERalphaLBD reported here, suggesting a higher degree of dynamic variability than expected for this critical substructure.

[1]  S. Fawell,et al.  A 22-amino-acid peptide restores DNA-binding activity to dimerization-defective mutants of the estrogen receptor , 1990, Molecular and cellular biology.

[2]  H. Samuels,et al.  A domain containing leucine-zipper-like motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors. , 1989, Molecular endocrinology.

[3]  A. M. Lesk,et al.  A toolkit for computational molecular biology. II. On the optimal superposition of two sets of coordinates , 1986 .

[4]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[5]  B. Katzenellenbogen,et al.  Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. , 1988, Endocrinology.

[6]  J. Abrahams,et al.  Methods used in the structure determination of bovine mitochondrial F1 ATPase. , 1996, Acta crystallographica. Section D, Biological crystallography.

[7]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[8]  R. Read.  Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[9]  R. Read,et al.  Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[11]  R. Blamey,et al.  Estradiol induction of retinoic acid receptors in human breast cancer cells. , 1993, Cancer research.

[12]  S. Fawell,et al.  Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor , 1990, Cell.

[13]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[14]  S V Evans,et al.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.

[15]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[16]  J. Katzenellenbogen,et al.  Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. , 1995, Molecular endocrinology.

[17]  H. Rochefort,et al.  Differential Interaction of Nuclear Receptors with the Putative Human Transcriptional Coactivator hTIF1* , 1997, The Journal of Biological Chemistry.

[18]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[19]  B. Katzenellenbogen,et al.  Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. , 1996, Chemistry & biology.

[20]  Mike Carson,et al.  RIBBONS 2.0 , 1991 .

[21]  B. Katzenellenbogen,et al.  A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. , 1996, Molecular endocrinology.

[22]  K. Umesono,et al.  Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. , 1996, Molecular endocrinology.

[23]  C. Green,et al.  Two separate mechanisms for ligand-independent activation of the estrogen receptor. , 1997, Molecular endocrinology.

[24]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[25]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[26]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[27]  Wei Yang,et al.  Crystal structure of the site-specific recombinase γδ resolvase complexed with a 34 by cleavage site , 1995, Cell.

[28]  John W. R. Schwabe,et al.  The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements , 1993, Cell.

[29]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[30]  P. Chambon,et al.  The N‐terminal part of TIF1, a putative mediator of the ligand‐dependent activation function (AF‐2) of nuclear receptors, is fused to B‐raf in the oncogenic protein T18. , 1995, The EMBO journal.

[31]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[32]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[33]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[34]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[35]  J. Nishikawa,et al.  Vitamin D receptor contains multiple dimerization interfaces that are functionally different. , 1995, Nucleic acids research.

[36]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.